Health Condition 1: K529- Noninfective gastroenteritis and colitis, unspecified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients willing to participate in the study. 2. Patients having the classical features of Grahani roga alongwith reduced appetite, tenesmus, and frequent passage of loose, mucoid stools. 4. Total duration of the illness less than one year.
Exclusion criteria
Exclusion criteria: 1. Patients not willing to participate in the study. 2. Patients of either sex below 30 year and above 65 years will be excluded from the study. 3. Patients with features of Sangraha grahani, Ghateeyantra grahani and evidence of malignancy, ulcerative colitis, Crohnâ??s disease, abdominal TB. 4. Total duration of the illness more than three years. 5. Patients on prolonged ( >6weeks) medication with corticosteroids, anti-depressants, anticholinergics, etc., or any other drugs that may have an influence on the outcome of the study. 6. Patients suffering from major systemic illness necessitating long term drug treatment Rheumatoid arthritis, tuberculosis, psycho-neuro-endocrinal disorders, etc. 7. Patients with concurrent serious hepatic disorder or renal disorders, severe pulmonary dysfunction, major cardiac problems or any other condition that may jeopardize the study. 8. Alcoholics and/or drug abusers. 9. History of hypersensitivity to the trial drug or any of its ingredients. 10. Pregnant/ lactating woman. 11. Patients who have completed participation in any other clinical trial during the past 6 months. 12. Any other conditions, which the principal investigator thinks may exclude the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Disease specific Ayurvedic subjective parameters on VAS 2. Rome III criteria for diagnosis of IBS. Timepoint: 12 weeks duration divided into 3 follow up of 4 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| 2. Assessment of Agni status: By using Agni grading scale developed by Singh RH et al. 3. Assessment of Ama developed by Singh RH et al Timepoint: 12 weeks duration divided into 3 follow up of 4 weeks. | — |
Countries
India
Contacts
Institute of Medical Sciences, BHU